Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials

The American Journal on Addictions
Henry R Kranzler, Allyson Gage

Abstract

In 2004, the United States Food and Drug Administration (FDA) approved acamprosate for use in conjunction with psychosocial support in the maintenance of abstinence in alcohol-dependent patients who are abstinent at treatment initiation. That approval was based primarily on a re-analysis of three European double-blind, placebo-controlled trials in which complete abstinence was the primary outcome measure. The current report presents data from the re-analysis of the pivotal trials, which were 13-, 48-, and 52-week studies. A total of 998 DSM-III-R alcohol-dependent patients were included in the studies, with the majority abstinent at randomization. Using a more stringent definition of abstinence, re-analysis of the rate of complete abstinence, percent days abstinent, and the time to first drink confirmed the original findings for the efficacy of acamprosate in the treatment of alcohol dependence. Rate of complete abstinence was significantly higher with acamprosate than placebo (p < .05); both percent days abstinent and time to first drink were also significantly greater among acamprosate-treated than placebo-treated patients (p < .01). These findings support the use of acamprosate in the treatment of alcohol dependence and illu...Continue Reading

Citations

Jan 24, 2012·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Peter D FriedmannUNKNOWN Mat Working Group Of CJ-Dats
Mar 30, 2010·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·Alexander DiehlFalk Kiefer
Sep 1, 2009·Journal of Addiction Medicine·Barbara J Mason, Philippe Lehert
Jul 22, 2008·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Charles P O'Brien
Jun 24, 2011·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Allison BragerJ David Glass
Feb 13, 2013·Substance Abuse : Research and Treatment·Stephanie L YahnM Foster Olive
Nov 14, 2013·Pharmacology, Biochemistry, and Behavior·Mary-Anne Enoch
Oct 14, 2014·Health & Justice·Peter D FriedmannUNKNOWN Jennifer Pankow for the CJ-DATS MATICCE Workgroup
Sep 5, 2012·Expert Review of Clinical Pharmacology·Peter Clapp
Sep 27, 2014·Expert Opinion on Drug Discovery·Peter R KufahlM Foster Olive
Mar 16, 2013·Journal of Substance Abuse Treatment·Cindy Parks ThomasMelissa M Rosen
Oct 30, 2012·Clinics in Liver Disease·Anthony P Albanese
May 4, 2011·Pharmacology, Biochemistry, and Behavior·M Foster OliveRobert J Malcolm
Jul 16, 2010·Journal of Substance Abuse Treatment·Maarten W J KoeterPhilippe Lehert
Nov 20, 2015·Progress in Neuro-psychopharmacology & Biological Psychiatry·C E Van SkikeK Nixon
Dec 15, 2010·Alcoholism, Clinical and Experimental Research·Ralitza GueorguievaStephanie S O'Malley
Oct 13, 2015·Psychiatry Research·Sarah G Helton, Falk W Lohoff
Jul 31, 2013·Alcoholism, Clinical and Experimental Research·Raye Z LittenHsiao-ye Yi
Jul 3, 2013·Current Opinion in Neurobiology·Johan Franck, Nitya Jayaram-Lindström
Jun 25, 2016·Child and Adolescent Psychiatric Clinics of North America·Cecilia Patrica Margret, Richard K Ries
Nov 11, 2010·The Annals of Pharmacotherapy·Thomas L SchwartzAnne Costello
Mar 27, 2009·Alcoholism, Clinical and Experimental Research·Henry R KranzlerJonathan Covault
Aug 15, 2018·Neuropsychopharmacology Reports·Nagisa SugayaKazutaka Ikeda

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.